Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -638.63% | 109.92% | -596.19% | 406.85% | -46.54% |
| Total Depreciation and Amortization | 10.21% | -37.94% | -1.75% | 1.93% | -3.15% |
| Total Amortization of Deferred Charges | 0.00% | 11.54% | -3.70% | -3.57% | 3.70% |
| Total Other Non-Cash Items | 376.00% | -117.31% | 1,303.07% | 33.81% | 23.83% |
| Change in Net Operating Assets | 17,417.39% | -101.35% | 116.76% | -411.97% | 510.33% |
| Cash from Operations | 694.66% | -122.05% | 143.42% | -322.20% | 344.12% |
| Capital Expenditure | -- | -- | 75.36% | -1,050.00% | 95.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -70.79% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -4,272.46% | -147.59% | -61.94% |
| Total Debt Issued | -199.79% | 551.35% | -85.17% | 2,431.78% | -113.76% |
| Total Debt Repaid | -0.22% | 0.00% | 0.00% | 0.22% | -0.22% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -34.07% | -81.56% | 38.49% | -307.40% |
| Cash from Financing | -372.78% | -82.33% | 202.23% | 255.76% | -402.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -255.24% | -86.87% | 674.34% | -867.24% | 184.31% |